5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine

Featuring The Fenmore Lectureship and The Redlich Lectureship

November 4-5, 2016

COURSE DIRECTORS:

Monica Mita, MD, MSc • Alain Mita, MD, MSc
Robert Figlin, MD • Razelle Kurzrock, MD

EXPLORE NEW AGENTS IN:

• Breast Cancer
• Lung Cancer
• GI Malignancies
• BRCA
• Synthetic Lethality
• Immuno-oncology

Cedars-Sinai Medical Center
Harvey Morse Conference Center
Los Angeles, CA 90048

In collaboration with UC San Diego Moores Cancer Center

For the latest course information and to register, visit cedars-sinai.edu/oncologycme
COURSE DESCRIPTION AND STATEMENT OF NEED

This important educational activity will provide front-line and oncology clinicians, oncology nurses, pharmacists, nurse practitioners, physician assistants and pharmacists with the most current information available about new agents in oncology and the translation of the latest research to their patients. The conference will cover drug and treatment updates with a focus on new agents in breast cancer, GI malignancies and lung cancer. We will also feature a mini-symposia that will cover BRCA and synthetic lethality.

EDUCATIONAL OBJECTIVES

• Evaluate clinical data and mechanism of action for newly approved drugs for the treatment of cancer
• Evaluate emerging clinical data regarding new agents and strategies for the treatment of advanced lung cancer, and apply clinical data to optimize patient outcomes
• Assess cancer immunotherapy treatments and their application in clinical practice based on a thorough understanding of how they work, their side effects and indications for use
• Evaluate emerging clinical data for new agents and evolving strategies for the treatment of breast cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety
• Evaluate clinical data on current and emerging agents for the treatment of myeloma and hematological malignancies
• Explore and discuss the concept of DNA repair impairment due to the BRCA system alteration and its therapeutic implications
• Evaluate emerging clinical data for new agents and evolving strategies for the treatment of renal cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety
• Use AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence-based national guidelines used in treatment planning

ACCREDITATION STATEMENT

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Cedars-Sinai Medical Center designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

The California State Board of Registered Nursing accepts courses approved by the ACCME for category 1 credit as meeting the educational requirements for license renewal.

POLICY ON DISCLOSURE

It is the policy of Cedars-Sinai Medical Center to ensure balance, independence, objectivity and scientific rigor in all its educational activities. Cedars-Sinai Medical Center assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter’s content for fair balance and absence of bias, scientific objectivity of studies utilized in the activity, and patient care recommendations.

While Cedars-Sinai Medical Center endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

Commercial support for this conference is pending. Companies that support this CME activity with educational grants will be acknowledged at the conference.

SPECIAL ACKNOWLEDGMENT

Cedars-Sinai Medical Center wishes to acknowledge the generosity of the Board of Governors Clinical Research Unit for its continuous support.

Cedars-Sinai also appreciates the support received from The Fenmore Lectureship and The Redlich Lectureship. The Fenmore Lectureship was initiated in 1978 by Mr. Maxwell J. Fenmore to present conferences on Oncology. The first annual meeting was held in 1979. The Redlich Lectureship was initiated in 1980 by Freida K. and Max H. Redlich as an endowed lectureship in Hematology to honor the outstanding CSMC Medical Staff and in particular the Division of Hematology/Oncology. In 1981, Mr. Redlich passed away from a rare hematological disorder.
FRIDAY, NOVEMBER 4, 2016

MINI-SYMPOSIA: BRCA AND SYNTHETIC LETHALITY

CO-CHAIRS: Monica Mita, MD, and Philomena McAndrew, MD

1:30-2:00 P.M. Registration

2:00-2:30  BRCA, synthetic lethality and its implication for breast cancer treatment  Pamela Munster, MD

2:30-2:50  BRCA-ness and ovarian cancer  Beth Karlan, MD

2:50-3:10  BRCA mutations and prostate cancer  Edwin Posadas, MD

3:10-3:30  BRCA mutations in pancreatic cancer and other solid tumors  Andrew Hendifar, MD

3:30-3:50  BRCA mutations: Implications for cancer screening and prevention  Simon Gayther, PhD

3:50-4:10  Q & A

4:10-6:00 P.M. Reception

SATURDAY, NOVEMBER 5, 2016

CO-CHAIRS: Razelle Kurzrock, MD, and Lawrence Piro, MD

7:30-8:00 A.M. Registration and breakfast

8:00-8:40  New drugs approved in 2015 and their mechanism of action  Alain Mita, MD

8:40-8:50  Q&A

8:50-10:30  New Developments in Immune Therapies Mini-Symposia

8:50-9:20  Personalizing immune therapies  Antoni Ribas, MD

9:20-9:50  Immunotherapy: Next-generation studies  Sandip Patel, MD

9:50-10:20  Immune cell therapies  Dan Kaufman, MD, PhD

10:20-10:40  Q&A

10:40-11:00  Break

11:00-11:20  Multiple myeloma: A new embarrassment of riches?  Robert Vescio, MD

11:20-11:30  Q&A

11:30-12:00  New therapeutic approaches for breast cancer  Monica Mita, MD

12:00-12:10  Q&A

12:10-1:00 P.M. Lunch
**CO-CHAIRS:** Steven Piantadosi, MD, PhD, and Barry Rosenbloom, MD

**KEYNOTE ADDRESS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00-1:45 P.M.</td>
<td><strong>Fenmore Lecture:</strong> Melanoma treatment in the era of immuno-oncology: A stand-up-to-cancer perspective</td>
<td>Patricia LoRusso, DO</td>
</tr>
<tr>
<td>1:45-2:00 P.M.</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>2:00-2:20</td>
<td>The evolving treatment paradigms for renal cancer</td>
<td>Robert Figlin, MD</td>
</tr>
<tr>
<td>2:20-2:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>2:30-3:00</td>
<td>Marrying genomics and immunotherapy: A perfect match</td>
<td>Razelle Kurzrock, MD</td>
</tr>
<tr>
<td>3:00-3:10</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>3:10-3:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:15-3:35</td>
<td><strong>Redlich Lecture:</strong> New developments for the treatment of brain tumors</td>
<td>Olivier Rixe, MD, PhD</td>
</tr>
<tr>
<td>3:35-3:45</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>3:45-4:05</td>
<td>New therapeutics for lung cancer</td>
<td>Ronald Natale, MD</td>
</tr>
<tr>
<td>4:05-4:15</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:15-4:35</td>
<td>NHL and leukemia treatment: 2016 updates</td>
<td>Ronald Paquette, MD</td>
</tr>
<tr>
<td>4:35-4:45</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>4:45 P.M.</td>
<td>Closing remarks and adjourn</td>
<td></td>
</tr>
</tbody>
</table>
REGISTRATION

5th Annual New Therapeutics in Oncology:
The Road to Personalized Medicine
FRIDAY-SATURDAY, NOVEMBER 4-5, 2016

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>PHYSICIAN</th>
<th>ALLIED HEALTH PROFESSIONAL</th>
<th>RESIDENT/FELLOW</th>
<th>INDUSTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received by October 17, 2016</td>
<td>$155</td>
<td>$85</td>
<td>$35</td>
<td>$200</td>
</tr>
<tr>
<td>Received after October 17, 2016</td>
<td>$195</td>
<td>$95</td>
<td>$50</td>
<td>$225</td>
</tr>
</tbody>
</table>

*Residents/fellows are eligible to attend for a reduced registration fee. In order to receive this reduced fee, please send the written proof of residency (i.e. letter from Program Director) along with your completed registration form or upload the written proof of residency online.

REGISTRATION METHODS:

ONLINE registration: cedars-sinai.edu/oncologycme

MAIL form to: Cedars-Sinai Medical Center
Office of Continuing Medical Education
Attn: Registration
8797 Beverly Boulevard, Suite #250
Los Angeles, CA 90048

FAX form to: 310-423-8596

For additional course or registration information call 310-423-5548.

Please print clearly

LAST NAME ___________________________________________ FIRST NAME ___________________________________________

DEGREE ___________________________________________ SPECIALTY ___________________________________________

ADDRESS ___________________________________________

CITY _________________________________________ STATE ________ ZIP _____________

PHONE ___________________________ FAX ___________________________

EMAIL ___________________________________________

* An email address is required to register for the conference.

CHECK ENCLOSED PAYABLE TO CSMC FOR $ __________

PLEASE CHARGE MY CREDIT CARD □ VISA □ MASTERCARD □ AMEX FOR $ __________

CC NUMBER ___________________________ CCV ________ EXP DATE _______ /

AUTHORIZED SIGNATURE ___________________________

HOW DID YOU LEARN ABOUT THIS CME ACTIVITY?

□ Brochure/Other Printed Materials □ Cedars-Sinai Website □ Email
□ Internet Search □ Colleague □ Past Participant
□ Internal Cedars-Sinai Communication □ Other __________

CONFIRMATION

To receive a registration confirmation, please provide your email address or fax number. If you do not receive a confirmation, please call 310-423-5548 to confirm your registration.

REFUND POLICY

All cancellations must be submitted in writing and refunds will be subject to a $50 administrative charge. No refunds will be given after October 24, 2016. Please email cancellation request to cme@cshs.org. If you do not receive confirmation of your cancellation via email, please call 310-423-5548.

CANCELLATION POLICY

Cedars-Sinai reserves the right to cancel or reschedule programs due to circumstances beyond its control or close registration when programs are oversubscribed. Registrants are advised against purchasing nonrefundable airline tickets until they receive registration confirmation. Cedars-Sinai is not responsible for penalties incurred as a result of canceled transportation costs.
*Alain C. Mita, MD  
**Course Co-director**  
Co-director, Experimental Therapeutics Program  
Associate Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

*Monica Mita, MD  
**Course Co-director**  
Co-director, Experimental Therapeutics Program  
Associate Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

*Robert A. Figlin, MD, FACP  
**Course Co-director**  
Steven Spielberg Family Chair in Hematology-Oncology  
Professor of Medicine and Biomedical Sciences  
Director, Division of Hematology/Oncology  
Deputy Director, Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

Razelle Kurzrock, MD  
**Course Co-director**  
Chief, Division of Hematology & Oncology  
Murray Professor of Medicine  
Senior Deputy Director, Clinical Science  
Director, Center for Personalized Cancer Therapy & Clinical Trials Office  
UC San Diego Moores Cancer Center  
La Jolla, CA

*Steven Piantadosi, MD, PhD  
Experimental Therapeutics Program Associate  
PHASE ONE Foundation Distinguished Chair and Director, Samuel Oschin Comprehensive Cancer Institute  
Professor, Department of Medicine  
Division of Hematology/Oncology  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

*Simon Gayther, PhD  
Cancer Biology & Therapeutics  
Graduate Research Education  
Cedars-Sinai  
Los Angeles, CA

*Andrew E. Hendifar, MD, MPH  
Co-Director, Pancreas Oncology  
Gastrointestinal and Neuroendocrine Malignancies  
Samuel Oschin Comprehensive Cancer Institute  
Cedars-Sinai  
Los Angeles, CA

*Beth Y. Karlan, MD  
Director, Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute  
Director, Division of Gynecologic Oncology  
Director, Gilda Radner Hereditary Cancer Program  
Board of Governors Chair in Gynecologic Oncology  
Professor, Obstetrics and Gynecology  
Cedars-Sinai  
Los Angeles, CA

Dan Kaufman, MD, PhD  
Professor, Department of Medicine  
UC San Diego  
La Jolla, CA

*Samuel Oschin Comprehensive Cancer Institute Member
ACTIVITY DETAILS

CONFERENCE LOCATION
Cedars-Sinai Medical Center
Harvey Morse Conference Center
Plaza Level, South Tower
8701 Gracie Allen Drive
Los Angeles, CA 90048

PARKING
Self-parking is available in the visitor parking lots P1, P2 (George Burns Road) or P4 (Sherbourne Drive).

HOTEL ACCOMMODATIONS
For a detailed list of hotels convenient to the medical center, please visit https://www.cedars-sinai.edu/Patients/Patient-and-Visitor-Resources/Los-Angeles-Area-Resources/Lodging-Near-Cedars-Sinai.aspx. When making reservations at any of these hotels, please be sure to mention that you are attending a conference at Cedars-Sinai to ensure you receive the best current reservation rate.

*Edwin M. Posadas, MD
Co-Medical Director, Urologic Oncology Center
Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute
Associate Professor, Medicine
Cedars-Sinai
Los Angeles, CA

Antoni Ribas, MD, PhD
Professor of Medicine,
Professor of Surgery,
Professor of Molecular and Medical Pharmacology
Department of Medicine, Hematology & Oncology
Ronald Reagan UCLA Medical Center
Los Angeles, CA

Barry E. Rosenbloom, MD
Partner, Tower Hematology Oncology Medical Group
Attending Staff, Department of Medicine
Division of Hematology/Oncology
Cedars-Sinai
Los Angeles, CA

Robert Vescio, MD
Medical Director, Multiple Myeloma and Amyloidosis Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

*Samuel Oschin Comprehensive Cancer Institute Member

VISITING FENMORE LECTURER
Patricia LoRusso, DO
Professor of Medicine (Medical Oncology)
Associate Director of Innovative Medicine
Yale Cancer Center
New Haven, CT

VISITING REDLICH LECTURER
Olivier Rixe, MD, PhD
Professor, Division of Hematology/Oncology
Cancer Center Associate Director, Clinical Research
The Dana Wood Endowed Chair in Cancer Therapeutics and Early Phase Clinical Research
University of New Mexico Comprehensive Cancer Center
Albuquerque, NM

* Edwin M. Posadas, MD
Co-Medical Director, Urologic Oncology Center
Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute
Associate Professor, Medicine
Cedars-Sinai
Los Angeles, CA

Antoni Ribas, MD, PhD
Professor of Medicine,
Professor of Surgery,
Professor of Molecular and Medical Pharmacology
Department of Medicine, Hematology & Oncology
Ronald Reagan UCLA Medical Center
Los Angeles, CA

Barry E. Rosenbloom, MD
Partner, Tower Hematology Oncology Medical Group
Attending Staff, Department of Medicine
Division of Hematology/Oncology
Cedars-Sinai
Los Angeles, CA

Robert Vescio, MD
Medical Director, Multiple Myeloma and Amyloidosis Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

*Samuel Oschin Comprehensive Cancer Institute Member

VISITING FENMORE LECTURER
Patricia LoRusso, DO
Professor of Medicine (Medical Oncology)
Associate Director of Innovative Medicine
Yale Cancer Center
New Haven, CT

VISITING REDLICH LECTURER
Olivier Rixe, MD, PhD
Professor, Division of Hematology/Oncology
Cancer Center Associate Director, Clinical Research
The Dana Wood Endowed Chair in Cancer Therapeutics and Early Phase Clinical Research
University of New Mexico Comprehensive Cancer Center
Albuquerque, NM

* Edwin M. Posadas, MD
Co-Medical Director, Urologic Oncology Center
Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute
Associate Professor, Medicine
Cedars-Sinai
Los Angeles, CA

Antoni Ribas, MD, PhD
Professor of Medicine,
Professor of Surgery,
Professor of Molecular and Medical Pharmacology
Department of Medicine, Hematology & Oncology
Ronald Reagan UCLA Medical Center
Los Angeles, CA

Barry E. Rosenbloom, MD
Partner, Tower Hematology Oncology Medical Group
Attending Staff, Department of Medicine
Division of Hematology/Oncology
Cedars-Sinai
Los Angeles, CA

Robert Vescio, MD
Medical Director, Multiple Myeloma and Amyloidosis Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

*Samuel Oschin Comprehensive Cancer Institute Member
Register now for:

5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine
FRIDAY-SATURDAY, NOVEMBER 4-5, 2016
CEDARS-SINAI

EXPLORE NEW AGENTS IN:
• Breast Cancer
• Lung Cancer
• GI Malignancies
• BRCA
• Synthetic Lethality
• Immuno-oncology

Earn up to 9.0 AMA PRA Category 1 Credits™